Skip to main content
SpringerLink
Log in

Analysis of Minimal Residual Disease with the Use of Rearrangements of Ig/TCR Genes Through RQ-PCR

  • Chapter
  • First Online:
Molecular Aspects of Hematologic Malignancies

Part of the book series: Principles and Practice ((PRINCIPLES))

  • 1327 Accesses

Abstract

The quantitative analysis of minimal residual disease (MRD) with the use of junctional regions of rearranged immunoglobulin (Ig) and T-cell (TCR) receptor genes as MRD target sequences is a complex, multi-step procedure. It includes: the processing of biological material, the detection, clonality assessment, identification, and selection of optimal MRD target sequences, and MRD analysis with the use of real-time quantitative polymerase chain reaction (RQ-PCR), which includes: probe and primer selection, standard curve preparation, testing the sensitivity of primers, DNA quality and quantity testing, quantitative MRD analysis, and data interpretation. Although this approach is laborious, it requires experienced and qualified personnel, and extensive standardization, it is applicable in more than 95 % of acute lymphoblastic leukemia (ALL) patients and enables MRD assessment with high sensitivity (10−4 – 10−5), which makes it a valuable tool for the management of ALL treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Arden B, Clark SP, Kabelitz D, Mak TW (1995) Human T-cell receptor variable gene segment families. Immunogenetics 42(6):455–500

    PubMed  CAS  Google Scholar 

  • Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A (2009) Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 27(3):377–384. doi:JCO.2008.17.606510.1200/JCO.2008.17.6065

    Google Scholar 

  • Bruggemann M, van der Velden VH, Raff T, Droese J, Ritgen M, Pott C, Wijkhuijs AJ, Gokbuget N, Hoelzer D, van Wering ER, van Dongen JJ, Kneba M (2004) Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia 18(4):709–719. doi:10.1038/sj.leu.24032632403263

    Google Scholar 

  • Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG, Asnafi V, Baruchel A, Bassan R, Benoit Y, Biondi A, Cave H, Dombret H, Fielding AK, Foa R, Gokbuget N, Goldstone AH, Goulden N, Henze G, Hoelzer D, Janka-Schaub GE, Macintyre EA, Pieters R, Rambaldi A, Ribera JM, Schmiegelow K, Spinelli O, Stary J, von Stackelberg A, Kneba M, Schrappe M, van Dongen JJ (2008) Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18–20 Sept 2008. Leukemia 24(3):521–535. doi:leu200926810.1038/leu.2009.268

    Google Scholar 

  • Cave H, van der Werfften Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European organization for research and treatment of cancer–childhood leukemia cooperative group. N Engl J Med 339(9):591–598

    Article  PubMed  CAS  Google Scholar 

  • Conter V, Bartram CR, Valsecchi MG, Schrauder A, Panzer-Grumayer R, Moricke A, Arico M, Zimmermann M, Mann G, De Rossi G, Stanulla M, Locatelli F, Basso G, Niggli F, Barisone E, Henze G, Ludwig WD, Haas OA, Cazzaniga G, Koehler R, Silvestri D, Bradtke J, Parasole R, Beier R, van Dongen JJ, Biondi A, Schrappe M (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 115(16):3206–3214. doi:blood-2009-10-24814610.1182/blood-2009-10-248146

    Google Scholar 

  • Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96(8):2691–2696

    PubMed  CAS  Google Scholar 

  • Dawidowska M, Jolkowska J, Szczepanski T, Derwich K, Wachowiak J, Witt M (2008) Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience. Arch Immunol Ther Exp (Warsz) 56(6):409–418. doi:10.1007/s00005-008-0045-y

    Article  Google Scholar 

  • Goulden N, Bader P, Van Der Velden V, Moppett J, Schilham M, Masden HO, Krejci O, Kreyenberg H, Lankester A, Revesz T, Klingebiel T, Van Dongen J (2003) Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia. Br J Haematol 122(1):24–29

    Article  PubMed  Google Scholar 

  • Kraszewska MD, Dawidowska M, Kosmalska M, Sedek L, Grzeszczak W, Szczepanski T, Witt M (2012) Immunoglobulin/T-cell receptor gene rearrangements in the diagnostic paradigm of pediatric T-cell acute lymphoblastic leukemia patients. Leuk Lymphoma. doi:10.3109/10428194.2011.654338

    PubMed  Google Scholar 

  • Kuppers R, Zhao M, Rajewsky K, Hansmann ML (1993) Detection of clonal B cell populations in paraffin-embedded tissues by polymerase chain reaction. Am J Pathol 143(1):230–239

    PubMed  CAS  Google Scholar 

  • Langerak AW, Szczepanski T, van der Burg M, Wolvers-Tettero IL, van Dongen JJ (1997) Heteroduplex PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell proliferations. Leukemia 11(12):2192–2199

    Article  PubMed  CAS  Google Scholar 

  • Paganin M, Zecca M, Fabbri G, Polato K, Biondi A, Rizzari C, Locatelli F, Basso G (2008) Minimal residual disease is an important predictive factor of outcome in children with relapsed ‘high-risk’ acute lymphoblastic leukemia. Leukemia 22(12):2193–2200. doi:leu200822710.1038/leu.2008.227

    Google Scholar 

  • Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H (2000) Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 95(3):790–794

    PubMed  CAS  Google Scholar 

  • Pongers-Willemse MJ, Verhagen OJ, Tibbe GJ, Wijkhuijs AJ, de Haas V, Roovers E, van der Schoot CE, van Dongen JJ (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12(12):2006–2014

    Article  PubMed  CAS  Google Scholar 

  • Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Grumayer ER, Biondi A, San Miguel JF, van Dongen JJM (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13(1):110–118

    Article  PubMed  CAS  Google Scholar 

  • Rowen L, Koop BF, Hood L (1996) The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 272(5269):1755–1762

    Article  PubMed  CAS  Google Scholar 

  • Schrappe M (2002) Risk-adapted therapy: lessons from childhood acute lymphoblastic leukemia. Hematol J 3(Supplement 2):127–132

    Google Scholar 

  • Szczepanski T, Flohr T, van der Velden VHJ, Bartram CR, van Dongen JJM (2002) Molecular monitoring of residual disease using antigen receptor genes in childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 15(1):37–57

    Article  PubMed  CAS  Google Scholar 

  • Szczepański T, Pongers-Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJ, van Wering ER, van Dongen JJ (1999) Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 93(12):4079–4085

    PubMed  Google Scholar 

  • Szczepański T, Willemse MJ, van Wering ER, van Weerden JF, Kamps WA, van Dongen JJ (2001) Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 15(9):1415–1423

    Article  PubMed  Google Scholar 

  • Szczepański T, van der Velden VH, Raff T, Jacobs DC, van Wering ER, Bruggemann M, Kneba M, van Dongen JJ (2003) Comparative analysis of T-cell receptor gene rearrangements at diagnosis and relapse of T-cell acute lymphoblastic leukemia (T-ALL) shows high stability of clonal markers for monitoring of minimal residual disease and reveals the occurrence of second T-ALL. Leukemia 17(11):2149–2156

    Article  PubMed  Google Scholar 

  • Szczepański T, van der Velden VH, Hoogeveen PG, de Bie M, Jacobs DC, van Wering ER, van Dongen JJ (2004) Vdelta2-Jalpha rearrangements are frequent in precursor-B-acute lymphoblastic leukemia but rare in normal lymphoid cells. Blood 103(10):3798–3804

    Article  PubMed  Google Scholar 

  • van der Velden VH, van Dongen JJ (2009) MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 538:115–150. doi:10.1007/978-1-59745-418-6_7

    Article  PubMed  Google Scholar 

  • van der Velden VH, Wijkhuijs JM, Jacobs DC, van Wering ER, van Dongen JJ (2002a) T cell receptor gamma gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukemia by real-time quantitative PCR analysis. Leukemia 16(7):1372–1380

    Article  PubMed  Google Scholar 

  • van der Velden VH, Willemse MJ, van der Schoot CE, Hahlen K, van Wering ER, van Dongen JJ (2002b) Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia 16(5):928–936

    Article  PubMed  Google Scholar 

  • van der Velden VH, Szczepanski T, Wijkhuijs JM, Hart PG, Hoogeveen PG, Hop WC, van Wering ER, van Dongen JJ (2003) Age-related patterns of immunoglobulin and T-cell receptor gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. Leukemia 17(9):1834–1844

    Article  PubMed  Google Scholar 

  • van der Velden VH, de Bie M, van Wering ER, van Dongen JJ (2006) Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica 91(5):679–682

    PubMed  Google Scholar 

  • van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ (2007a) Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 21(4):604–611

    PubMed  Google Scholar 

  • van der Velden VH, Panzer-Grumayer ER, Cazzaniga G, Flohr T, Sutton R, Schrauder A, Basso G, Schrappe M, Wijkhuijs JM, Konrad M, Bartram CR, Masera G, Biondi A, van Dongen JJ (2007b) Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 21(4):706–713

    PubMed  Google Scholar 

  • van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig WD, Basso G, de Bruijn MA, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WC, Riehm H, Bartram CR (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352(9142):1731–1738

    Article  PubMed  Google Scholar 

  • van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, van Krieken JH, Droese J, Gonzalez D, Bastard C, White HE, Spaargaren M, Gonzalez M, Parreira A, Smith JL, Morgan GJ, Kneba M, Macintyre EA (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17(12):2257–2317

    Article  PubMed  Google Scholar 

  • Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA, van Wering ER, van Dongen JJ, van der Schoot CE (2000) Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14(8):1426–1435

    Article  PubMed  CAS  Google Scholar 

  • Willems P, Verhagen O, Segeren C, Veenhuizen P, Guikema J, Wiemer E, Groothuis L, Jong TB, Kok H, Bloem A, Bos N, Vellenga E, Mensink E, Sonneveld P, Lokhorst H, van Der Schoot E, Raymakers R (2000) Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch hematology-oncology group. Blood 96(1):63–70

    PubMed  CAS  Google Scholar 

  • Willemse MJ, Seriu T, Hettinger K, d’Aniello E, Hop WC, Panzer-Grumayer ER, Biondi A, Schrappe M, Kamps WA, Masera G, Gadner H, Riehm H, Bartram CR, van Dongen JJ (2002) Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 99(12):4386–4393

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Genetics, Institute of Human Genetics, Polish Academy of Sciences, Strzeszyńska 32, 60-479, Poznań, Poland

    Małgorzata Dawidowska & Michał Witt

  2. Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands

    Vincent H. J. van der Velden

  3. International Institute of Molecular and Cell Biology, Trojdena 4, 02-109, Warsaw, Poland

    Michał Witt

  4. Department of Pediatric Hematology and Oncology, Medical University of Silesia, 3 Maja 13/15, 41-800, Zabrze, Poland

    Tomasz Szczepański

Authors
  1. Małgorzata Dawidowska
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vincent H. J. van der Velden
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michał Witt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tomasz Szczepański
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Małgorzata Dawidowska .

Editor information

Editors and Affiliations

  1. International Institute of Molecular and, Trojdena 4, Warszawa, 02-109, Poland

    Michal Witt

  2. , Institute of Human Genetics, Polish Academy of Sciences, ul. Strzeszynska 32, Poznan, 60479, Poland

    Malgorzata Dawidowska

  3. , Department of Pediatric Hematology, Silesian Academy of Medicine, 3 Maja 13-15, Zabrze, 41800, Poland

    Tomasz Szczepanski

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Dawidowska, M., van der Velden, V.H.J., Witt, M., Szczepański, T. (2012). Analysis of Minimal Residual Disease with the Use of Rearrangements of Ig/TCR Genes Through RQ-PCR. In: Witt, M., Dawidowska, M., Szczepanski, T. (eds) Molecular Aspects of Hematologic Malignancies. Principles and Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29467-9_23

Download citation

Publish with us

Policies and ethics

Search

Navigation